This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesInsider TradesTrendsBuy This Stock VACC vs. PROC, OPTN, WHWK, VIRI, PYRGF, VHAQ, ATNM, AADI, EGRX, and OSTXShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Procaps Group (PROC), OptiNose (OPTN), Whitehawk Therapeutics (WHWK), Virios Therapeutics (VIRI), PyroGenesis Canada (PYRGF), Viveon Health Acquisition (VHAQ), Actinium Pharmaceuticals (ATNM), Aadi Bioscience (AADI), Eagle Pharmaceuticals (EGRX), and OS Therapies (OSTX). Vaccitech vs. Its Competitors Procaps Group OptiNose Whitehawk Therapeutics Virios Therapeutics PyroGenesis Canada Viveon Health Acquisition Actinium Pharmaceuticals Aadi Bioscience Eagle Pharmaceuticals OS Therapies Vaccitech (NASDAQ:VACC) and Procaps Group (NASDAQ:PROC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Which has better earnings & valuation, VACC or PROC? Procaps Group has higher revenue and earnings than Vaccitech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaccitech$13.42M3.04$5.34M-$1.43-0.74Procaps Group$409.92M0.26$42.54MN/AN/A Does the media favor VACC or PROC? In the previous week, Vaccitech's average media sentiment score of 0.00 equaled Procaps Group'saverage media sentiment score. Company Overall Sentiment Vaccitech Neutral Procaps Group Neutral Which has more volatility and risk, VACC or PROC? Vaccitech has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Procaps Group has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Is VACC or PROC more profitable? Procaps Group has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Procaps Group's return on equity of 0.00% beat Vaccitech's return on equity.Company Net Margins Return on Equity Return on Assets Vaccitech-409.18% -23.41% -20.85% Procaps Group N/A N/A N/A Do institutionals & insiders believe in VACC or PROC? 26.1% of Vaccitech shares are owned by institutional investors. 6.0% of Vaccitech shares are owned by insiders. Comparatively, 19.9% of Procaps Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryProcaps Group beats Vaccitech on 7 of the 9 factors compared between the two stocks. Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.86M$799.39M$5.57B$9.02BDividend YieldN/A4.84%5.25%4.03%P/E Ratio-0.741.3027.2020.15Price / Sales3.04227.16419.15184.83Price / Cash19.3023.4437.0657.97Price / Book0.166.178.085.60Net Income$5.34M-$27.58M$3.16B$248.50M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$1.06+7.6%N/A-31.1%$40.86M$13.42M-0.7433Gap UpPROCProcaps GroupN/A$0.95-40.3%N/A-62.2%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeOPTNOptiNose0.7372 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190WHWKWhitehawk TherapeuticsN/A$2.01+1.0%N/AN/A$93.75M$25.98M0.0040High Trading VolumeVIRIVirios TherapeuticsN/A$4.84+5.2%$5.00+3.3%+1,754.4%$93.21MN/A-17.935PYRGFPyroGenesis Canada0.1054 of 5 stars$0.35+1.2%N/A-50.0%$64.48M$9.14M-5.8390News CoverageVHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeATNMActinium Pharmaceuticals3.0347 of 5 stars$1.58+10.5%$4.00+153.2%N/A$49.29MN/A-1.1430Positive NewsAADIAadi Bioscience0.659 of 5 stars$1.99+0.5%$1.67-16.2%+43.2%$49.15M$25.07M-0.8740EGRXEagle Pharmaceuticals2.5847 of 5 stars$3.65+12.3%N/A-39.9%$47.40M$257.55M0.00100News CoverageGap DownOSTXOS Therapies2.6294 of 5 stars$1.66+2.5%$18.00+984.3%N/A$46.64MN/A-1.93N/A Related Companies and Tools Related Companies Procaps Group Competitors OptiNose Competitors Whitehawk Therapeutics Competitors Virios Therapeutics Competitors PyroGenesis Canada Competitors Viveon Health Acquisition Competitors Actinium Pharmaceuticals Competitors Aadi Bioscience Competitors Eagle Pharmaceuticals Competitors OS Therapies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VACC) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.